Clinical Trial Results:
A MULTICENTER OPEN LABEL PHASE II STUDY OF THE EFFICACY AND SAFETY OF AMG 479, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST INSULIN-LIKE GROWTH FACTOR TYPE 1 RECEPTOR (IGF-1R) AS SECOND LINE THERAPY IN PATIENTS WITH RECURRENT PLATINUMSENSITIVE OVARIAN CANCER
Summary
|
|
EudraCT number |
2008-001552-44 |
Trial protocol |
FR DE ES IE |
Global completion date |
23 May 2013
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
11 Dec 2016
|
First version publication date |
11 Dec 2016
|
Other versions |
|
Summary report(s) |
CSR summary EudraCT 2008-001552-44 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.